Chemed Stock Forecast, Price & News

+0.05 (+0.01 %)
(As of 08/2/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume165,783 shs
Average Volume94,684 shs
Market Capitalization$7.59 billion
P/E Ratio25.57
Dividend Yield0.29%
30 days | 90 days | 365 days | Advanced Chart
Receive CHE News and Ratings via Email

Sign-up to receive the latest news and ratings for Chemed and its competitors with MarketBeat's FREE daily newsletter.

Chemed logo

About Chemed

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers in the United States. It operates in two segments, VITAS and Roto-Rooter. The company also offers plumbing, drain cleaning, water restoration, and other related services to residential and commercial customers through company-owned branches and independent contractors, and franchised locations. Chemed Corporation was incorporated in 1970 and is headquartered in Cincinnati, Ohio.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value





Social Links


Overall MarketRank

2.87 out of 5 stars

Medical Sector

4th out of 2,226 stocks

Home Health Care Services Industry

1st out of 12 stocks

Analyst Opinion: 2.5Community Rank: 4.1Dividend Strength: 3.3Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Chemed (NYSE:CHE) Frequently Asked Questions

Is Chemed a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chemed in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Chemed stock.
View analyst ratings for Chemed
or view top-rated stocks.

What stocks does MarketBeat like better than Chemed?

Wall Street analysts have given Chemed a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Chemed wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Chemed?

Chemed saw a increase in short interest during the month of July. As of July 15th, there was short interest totaling 173,600 shares, an increase of 36.6% from the June 30th total of 127,100 shares. Based on an average daily trading volume, of 89,000 shares, the short-interest ratio is presently 2.0 days. Approximately 1.1% of the company's shares are short sold.
View Chemed's Short Interest

When is Chemed's next earnings date?

Chemed is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Chemed

How were Chemed's earnings last quarter?

Chemed Co. (NYSE:CHE) issued its quarterly earnings results on Monday, July, 26th. The company reported $4.60 earnings per share for the quarter, topping the consensus estimate of $4.29 by $0.31. The business earned $532.26 million during the quarter, compared to analysts' expectations of $511.85 million. Chemed had a trailing twelve-month return on equity of 35.40% and a net margin of 14.30%. The firm's quarterly revenue was up 6.0% compared to the same quarter last year. During the same period in the previous year, the business earned $4.41 earnings per share.
View Chemed's earnings history

How has Chemed's stock been impacted by COVID-19 (Coronavirus)?

Chemed's stock was trading at $414.05 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CHE stock has increased by 15.0% and is now trading at $476.07.
View which stocks have been most impacted by COVID-19

How often does Chemed pay dividends? What is the dividend yield for Chemed?

Chemed announced a quarterly dividend on Monday, May 17th. Shareholders of record on Thursday, May 27th will be given a dividend of $0.34 per share on Wednesday, June 16th. This represents a $1.36 dividend on an annualized basis and a yield of 0.29%. The ex-dividend date of this dividend is Wednesday, May 26th.
View Chemed's dividend history

Is Chemed a good dividend stock?

Chemed pays an annual dividend of $1.36 per share and currently has a dividend yield of 0.29%. Chemed has been increasing its dividend for 12 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of Chemed is 7.52%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Chemed will have a dividend payout ratio of 7.03% next year. This indicates that Chemed will be able to sustain or increase its dividend.
View Chemed's dividend history.

What guidance has Chemed issued on next quarter's earnings?

Chemed issued an update on its FY21 earnings guidance on Tuesday, July, 27th. The company provided earnings per share (EPS) guidance of $18.20-18.50 for the period, compared to the Thomson Reuters consensus estimate of $17.77.

What price target have analysts set for CHE?

2 brokers have issued 1-year price objectives for Chemed's shares. Their forecasts range from $580.00 to $609.00. On average, they anticipate Chemed's share price to reach $594.50 in the next year. This suggests a possible upside of 24.9% from the stock's current price.
View analysts' price targets for Chemed
or view top-rated stocks among Wall Street analysts.

Who are Chemed's key executives?

Chemed's management team includes the following people:
  • Mr. Kevin J. McNamara, CEO, Pres & Director (Age 67, Pay $5.71M)
  • Mr. David P. Williams, Exec. VP & CFO (Age 60, Pay $2.74M)
  • Mr. Michael D. Witzeman CPA, MBA, VP & Controller (Age 50, Pay $991.14k)
  • Mr. Spencer S. Lee, Exec. VP (Age 65, Pay $1.9M)
  • Mr. Nicholas Michael Westfall, Exec. VP (Age 42, Pay $2.11M)
  • Ms. Lisa A. Reinhard, VP, Chief Admin. Officer & Assistant Sec.
  • Sherri Warner, Director of Investor Relations
  • Mr. Brian C. Judkins, VP, Sec. & Chief Legal Officer (Age 40)
  • Mr. Thomas C. Hutton, VP & Director (Age 70)

What is Kevin J. McNamara's approval rating as Chemed's CEO?

1 employees have rated Chemed CEO Kevin J. McNamara on Glassdoor.com. Kevin J. McNamara has an approval rating of 100% among Chemed's employees. This puts Kevin J. McNamara in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Chemed's key competitors?

What other stocks do shareholders of Chemed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Chemed investors own include AT&T (T), The Home Depot (HD), Johnson & Johnson (JNJ), AbbVie (ABBV), Abbott Laboratories (ABT), CVS Health (CVS), The Boeing (BA), UnitedHealth Group (UNH), Verizon Communications (VZ) and Chevron (CVX).

What is Chemed's stock symbol?

Chemed trades on the New York Stock Exchange (NYSE) under the ticker symbol "CHE."

Who are Chemed's major shareholders?

Chemed's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Boston Trust Walden Corp (1.07%), Fisher Asset Management LLC (0.98%), Copeland Capital Management LLC (0.63%), Trinity Street Asset Management LLP (0.28%), Alliancebernstein L.P. (0.20%) and New York State Common Retirement Fund (0.18%). Company insiders that own Chemed stock include Andrea R Lindell, David Patrick Williams, Donald E Saunders, Frank E Wood, George J Walsh III, Kevin J Mcnamara, Michael D Witzeman, Naomi C Dallob, Nicholas Michael Westfall, Patrick P Grace, Spencer S Lee, Thomas P Rice and Walter L Krebs.
View institutional ownership trends for Chemed

Which institutional investors are selling Chemed stock?

CHE stock was sold by a variety of institutional investors in the last quarter, including Trinity Street Asset Management LLP, Fisher Asset Management LLC, New York State Common Retirement Fund, State of Michigan Retirement System, Copeland Capital Management LLC, Hanson & Doremus Investment Management, Miracle Mile Advisors LLC, and Princeton Portfolio Strategies Group LLC. Company insiders that have sold Chemed company stock in the last year include Donald E Saunders, Kevin J Mcnamara, Michael D Witzeman, Nicholas Michael Westfall, Spencer S Lee, and Thomas P Rice.
View insider buying and selling activity for Chemed
or view top insider-selling stocks.

Which institutional investors are buying Chemed stock?

CHE stock was bought by a variety of institutional investors in the last quarter, including Boston Trust Walden Corp, State of Alaska Department of Revenue, Alliancebernstein L.P., Aptus Capital Advisors LLC, Kornitzer Capital Management Inc. KS, Marshall Financial Group LLC, Capital Insight Partners LLC, and TrimTabs Asset Management LLC.
View insider buying and selling activity for Chemed
or or view top insider-buying stocks.

How do I buy shares of Chemed?

Shares of CHE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Chemed's stock price today?

One share of CHE stock can currently be purchased for approximately $476.07.

How much money does Chemed make?

Chemed has a market capitalization of $7.59 billion and generates $2.08 billion in revenue each year. The company earns $319.47 million in net income (profit) each year or $18.08 on an earnings per share basis.

How many employees does Chemed have?

Chemed employs 15,544 workers across the globe.

When was Chemed founded?

Chemed was founded in 1970.

What is Chemed's official website?

The official website for Chemed is www.chemed.com.

Where are Chemed's headquarters?

Chemed is headquartered at 255 EAST FIFTH STREET SUITE 2600, CINCINNATI OH, 45202.

How can I contact Chemed?

Chemed's mailing address is 255 EAST FIFTH STREET SUITE 2600, CINCINNATI OH, 45202. The company can be reached via phone at 513-762-6690.

This page was last updated on 8/2/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.